Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

January 6, 2014

Primary Completion Date

June 24, 2014

Study Completion Date

June 24, 2014

Conditions
Epidermolysis Bullosa
Interventions
DRUG

SD-101 dermal cream (3%)

SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.

DRUG

SD-101 Dermal Cream (6%)

SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.

DRUG

Vehicle (SD-101 0%)

A white, crystalline powder that is formulated within an odorless, soft, white cream base. It contains no allantoin, only excipients.

Trial Locations (7)

27516

Chapel Hill

60611

Chicago

63110

St Louis

78218

San Antonio

94304

Palo Alto

98105

Seattle

07601

Hackensack

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Amicus Therapeutics

INDUSTRY

lead

Scioderm, Inc.

INDUSTRY